Alert Day, sponsored by the American Diabetes Association, was created to raise Americans’ awareness of their risks of developing type-2 diabetes. Celebrated earlier this week, Alert Day once again brought the growing concerns over Actos into focus. With the number of diabetic Americans expected to rise with our aging population, Actos was once viewed as a viable alternative to Avandia.
The belief in Actos as a viable alternative to the type-2 diabetes pill Avandia was dashed as complaints in 2011 for side effects including bladder cancer and heart failure increased 250% over complaints in 2010. Independent researchers have found that Actos users have a 40% higher chance of developing bladder cancer after they have taken the drug for longer than a year. Both Germany and France have pulled Actos off the shelves. The FDA is yet to pull the drug from American shelves, but has added stronger warnings to the label and continues to monitor ongoing research.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.